Bariatric Surgery and Pharmacokinetics of Chlorprothixene

Bariatric Surgery and Pharmacokinetics of Chlorprothixene: BAR-MEDS Chlorprothixene

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03449485

Enrollment

Registered

2018-02-28

Start date

2018-01-02

Completion date

2026-12-31

Last updated

2025-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Morbid

Keywords

Bariatric surgery, Gastrointestinal tract, Biological availability, Pharmacokinetics, Chlorprothixene

Brief summary

Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study we investigate the pharmacokinetic effects of bariatric surgery on chlorprothixene.

Interventions

DRUGChlorprothixene

Patients are tested for their normal prescription chlorprothixene medication

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway * Being a Norwegian citizen

Exclusion criteria

* Having previously undergone resections in the GI-tract

Design outcomes

Primary

Measure	Time frame
Chlorprothixene concentration in blood serum (area under curve (AUC))	From baseline to 1 year postoperatively

Countries

Norway

Contacts

Primary ContactMagnus Strømmen, MSc

magnus.strommen@stolav.no0047 72829970

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026